REGENXBIO

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell REGENXBIO and other ETFs, options, and stocks.

About RGNX

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. 

CEO
Curran M. Simpson
CEOCurran M. Simpson
Employees
353
Employees353
Headquarters
Rockville, Maryland
HeadquartersRockville, Maryland
Founded
2008
Founded2008
Employees
353
Employees353

RGNX Key Statistics

Market cap
441.18M
Market cap441.18M
Price-Earnings ratio
-2.50
Price-Earnings ratio-2.50
Dividend yield
Dividend yield
Average volume
923.37K
Average volume923.37K
High today
$8.80
High today$8.80
Low today
$8.01
Low today$8.01
Open price
$8.68
Open price$8.68
Volume
1.47M
Volume1.47M
52 Week high
$16.19
52 Week high$16.19
52 Week low
$5.04
52 Week low$5.04

Stock Snapshot

As of today, REGENXBIO(RGNX) shares are valued at $8.57. The company's market cap stands at 441.18M, with a P/E ratio of -2.50.

During the trading session on 2026-03-05, REGENXBIO(RGNX) shares reached a daily high of $8.80 and a low of $8.01. At a current price of $8.57, the stock is +7.0% higher than the low and still -2.6% under the high.

Trading activity shows a volume of 1.47M, compared to an average daily volume of 923.37K.

The stock's 52-week range extends from a low of $5.04 to a high of $16.19.

The stock's 52-week range extends from a low of $5.04 to a high of $16.19.

RGNX News

TipRanks 44m
RegenXBio Earnings Call Balances Gene Therapy Risks

RegenXBio Inc. ((RGNX)) has held its Q4 earnings call. Read on for the main highlights of the call. Claim 70% Off TipRanks Premium Unlock hedge fund-level data...

TipRanks 13h
Regenxbio reports Q4 EPS ($1.30) vs. ($1.01) last year

Reports Q4 revenue $30.3M vs. $21.2M last year. “We are rapidly advancing our late-stage pipeline of gene therapies to treat rare and retinal diseases with sign...

TipRanks 3d
When a Clinical Hold Disrupts a Gene Therapy Program: What Happened to Regenxbio Stock

Regenxbio Inc. (RGNX) investors saw shares fall sharply in January 2026 after the company disclosed that the U.S. Food and Drug Administration (FDA) had placed...

Analyst ratings

92%

of 12 ratings
Buy
91.7%
Hold
8.3%
Sell
0%

More RGNX News

TipRanks 6d
RegenXBio’s RGX-121 Hunter Syndrome Trial Faces Suspension: What Investors Should Know

RegenXBio Inc. (RGNX) announced an update on their ongoing clinical study. RegenXBio Inc. (RGNX) is running a late stage study of RGX-121, a gene therapy for c...

People also own

Based on the portfolios of people who own RGNX. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.